Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
90 hedge funds and large institutions have $180M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 11 closing their positions.
399% more call options, than puts
Call options by funds: $639K | Put options by funds: $128K
43% more capital invested
Capital invested by funds: $125M → $180M (+$54.4M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
2% more funds holding
Funds holding: 88 → 90 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.22M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.36M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$1.24M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$684K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$384K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.59M |
| 2 |
Renaissance Technologies
New York
|
-$1.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$927K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$906K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$696K |
JNCE Hedge Fund Activity: Q2 2020 in Review
90 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2020, worth a combined $180M — up 43% from $125M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new JNCE positions and 11 closed out — a net gain of 2 holders — while 29 added to existing stakes and 32 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.22M. The largest seller was Bridgeway Capital Management, cutting an estimated $1.59M.
- 90 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2020, up from 88 in Q1 2020.
- Funds reported $180M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2020, up 43% quarter-over-quarter.
- 13 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2020 and 11 closed out, a net change of +2 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2020 was Citadel Advisors, an estimated $2.22M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2020 was Bridgeway Capital Management, an estimated $1.59M sold.
Based on aggregated 13F filings for Q2 2020.